Dexamethasone intravitreal implant for macular edema: a pilot study in a public health center
Main Article Content
Abstract
Introduction: Macula edema consists in one of the most common causes of visual impairment. Objective: To evaluate the safety and efficacy of continuous release of 0.7 mg dexamethasone (using implantable device) for treatment of macular edema. Methods: Cross-sectional observational study of 16 patients treated with 0.7 mg dexamethasone intraocular implant. Visual acuity, intraocular pressure and central macular thickness were recorded at baseline, 1-month and 3-month follow-up. Results: 15 eyes of 13 patients were included. Most eyes (n=9) improve visual acuity from baseline at 1-month follow-up; this improvement persisted through 3-monyh follow-up in six eyes. The central macular thickness decreased in the majority of the subjects at 1-month (n=12) and at 3-month (n=10) follow-up. Three eyes presented with elevated intraocular pressure. Conclusion: Dexamethasone implant can both reduce the risk of vision loss and improve anatomical features of macular edema due to several pathologies studied. This implant may be used safely and should be considered a therapeutic option to Brazilian Public Health System.
Downloads
Article Details
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.References
2. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4-10. https://doi.org/10.2174/1874364101307010004
3. Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-203. https://doi.org/10.1056/NEJMoa1414264
4. Bolinger MT, Antonetti DA. Antonetti. Moving past anti-VEGF: novel therapies for treating diabetic retinopathy. Int J Mol Sci. 2016;17(9):1498. https://doi.org/10.3390/ijms17091498
5. Kanra AY, Akçakaya AA, Yaylalı SA, Altınel MG, Sevimli N. The efficacy and safety of intravitreal dexamethasone implant for the treatment of macular edema related to retinal vein occlusion: real-life data and prognostic factors in a Turkish population. Turk J Ophthalmol. 2017;47(6):331-7. https://doi.org/10.4274/tjo.75317
6. Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545-53. https://doi.org/10.1001/archophthalmol.2010.339
7. Chhablani J, Jhingan M, Goud A, Vupparaboina KK, Das T. Macular edema resolution assessment with implantable dexamethasone in diabetic retinopathy (MERIT): a pilot study. Clin Ophthalmol. 2018;12:1205-11. https://doi.org/10.2147/OPTH.S163681
8. Demir G, Ozkaya A, Yuksel E, Erdogan G, Tunc U, Ocal MC, et al. Early and Late Switch from Ranibizumab to an intravitreal Dexamethasone implant in patients with Diabetic macular edema in the event of a poor anatomical response. Clin Drug Investig. 2020;40(2):119-28. https://doi.org/10.1007/s40261-019-00865-7
9. Hufendiek K, Pielen A, Framme C. Strategies of Intravitreal Injections with Anti-VEGF: "Pro re Nata versus Treat and Extend". Klin Monbl Augenheilkd. 2018;235(8):930-9. https://doi.org/10.1055/s-0042-122340